698 related articles for article (PubMed ID: 38438349)
21. Modified study designs to expand treatment options in personalised oncology: a multistakeholder view.
Le Tourneau C; André F; Helland Å; Mileshkin L; Minnaard W; Schiel A; Taskén K; Thomas DM; Veronese ML; Durán-Pacheco G; Leyens L; Rufibach K; Thomas M; Krämer A
Eur J Cancer; 2023 Nov; 194():113278. PubMed ID: 37820553
[TBL] [Abstract][Full Text] [Related]
22. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
23. Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction.
Shah SJ
J Cardiovasc Transl Res; 2017 Jun; 10(3):322-336. PubMed ID: 28681133
[TBL] [Abstract][Full Text] [Related]
24. Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development.
Peeva E; Banerjee A; Banfield C; Soma K; Christensen J; Menon S; Vincent MS; Dolsten M
Drug Discov Today; 2024 May; 29(5):103948. PubMed ID: 38460567
[TBL] [Abstract][Full Text] [Related]
25. Basket Trials and the MD Anderson Precision Medicine Clinical Trials Platform.
Said R; Tsimberidou AM
Cancer J; 2019; 25(4):282-286. PubMed ID: 31335392
[TBL] [Abstract][Full Text] [Related]
26. Bayesian basket trial design with false-discovery rate control.
Zabor EC; Kane MJ; Roychoudhury S; Nie L; Hobbs BP
Clin Trials; 2022 Jun; 19(3):297-306. PubMed ID: 35128970
[TBL] [Abstract][Full Text] [Related]
27. Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.
Polley MC; Cheung YK
JCO Precis Oncol; 2019; 3():. PubMed ID: 32923846
[TBL] [Abstract][Full Text] [Related]
28. Definitions and statistical properties of master protocols for personalized medicine in oncology.
Renfro LA; Mandrekar SJ
J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
[TBL] [Abstract][Full Text] [Related]
29. Bayesian basket trial design with exchangeability monitoring.
Hobbs BP; Landin R
Stat Med; 2018 Nov; 37(25):3557-3572. PubMed ID: 29984488
[TBL] [Abstract][Full Text] [Related]
30. Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples.
Renfro LA; Sargent DJ
Ann Oncol; 2017 Jan; 28(1):34-43. PubMed ID: 28177494
[TBL] [Abstract][Full Text] [Related]
31. The New NCI Precision Medicine Trials.
Harris LN; Blanke CD; Erba HP; Ford JM; Gray RJ; LeBlanc ML; Hu-Lieskovan S; Litzow MR; Luger SM; Meric-Bernstam F; O'Dwyer PJ; Othus MKD; Politi K; Shepherd LE; Allegra CJ; Chen HX; Ivy SP; Korde LA; Little RF; McShane LM; Moscow JA; Patton DR; Thurin M; Yee LM; Doroshow JH
Clin Cancer Res; 2023 Dec; 29(23):4728-4732. PubMed ID: 37531248
[TBL] [Abstract][Full Text] [Related]
32. Advancing cancer drug development through precision medicine and innovative designs.
Zhang W; Wang J; Menon S
J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
[TBL] [Abstract][Full Text] [Related]
33. Translational precision medicine: an industry perspective.
Hartl D; de Luca V; Kostikova A; Laramie J; Kennedy S; Ferrero E; Siegel R; Fink M; Ahmed S; Millholland J; Schuhmacher A; Hinder M; Piali L; Roth A
J Transl Med; 2021 Jun; 19(1):245. PubMed ID: 34090480
[TBL] [Abstract][Full Text] [Related]
34. Study designs for clinical trials applied to personalised medicine: a scoping review.
Superchi C; Brion Bouvier F; Gerardi C; Carmona M; San Miguel L; Sánchez-Gómez LM; Imaz-Iglesia I; Garcia P; Demotes J; Banzi R; Porcher R;
BMJ Open; 2022 May; 12(5):e052926. PubMed ID: 35523482
[TBL] [Abstract][Full Text] [Related]
35. Master protocol trials in oncology: Review and new trial designs.
Hirakawa A; Asano J; Sato H; Teramukai S
Contemp Clin Trials Commun; 2018 Dec; 12():1-8. PubMed ID: 30182068
[TBL] [Abstract][Full Text] [Related]
36. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
37. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Antoniou M; Jorgensen AL; Kolamunnage-Dona R
PLoS One; 2016; 11(2):e0149803. PubMed ID: 26910238
[TBL] [Abstract][Full Text] [Related]
38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
39. Reporting of master protocols towards a standardized approach: A systematic review.
Siden EG; Park JJ; Zoratti MJ; Dron L; Harari O; Thorlund K; Mills EJ
Contemp Clin Trials Commun; 2019 Sep; 15():100406. PubMed ID: 31334382
[TBL] [Abstract][Full Text] [Related]
40. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials.
Collignon O; Gartner C; Haidich AB; James Hemmings R; Hofner B; Pétavy F; Posch M; Rantell K; Roes K; Schiel A
Clin Pharmacol Ther; 2020 May; 107(5):1059-1067. PubMed ID: 32017052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
